MDS
Clinical trials for MDS explained in plain language.
Never miss a new study
Get alerted when new MDS trials appear
Sign up with your email to follow new studies for MDS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for rare blood cancers
Disease control OngoingThis study looks at whether adding venetoclax to standard chemotherapy (HMAs) works better than chemotherapy alone for people newly diagnosed with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 224 adults will be observed to see how m…
Matched conditions: MDS
Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated May 17, 2026 05:30 UTC
-
New antibody drug aims to wipe out hidden leukemia cells
Disease control OngoingThis study tests an experimental drug called vibecotamab in 42 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer did not fully respond to standard treatments. The drug is designed to help the immune system find and destroy remaining cancer ce…
Matched conditions: MDS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:29 UTC
-
Younger relatives may be better stem cell donors for blood cancer patients
Disease control OngoingThis study looks at whether using stem cells from a younger, more distant relative leads to better survival than using cells from an older immediate family member for people with leukemia or MDS. About 232 participants will be randomly assigned to receive a transplant from either…
Matched conditions: MDS
Phase: PHASE3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated May 15, 2026 11:52 UTC
-
New hope for rare blood cancers? fedratinib trial underway
Disease control OngoingThis study tests a drug called fedratinib in 25 adults with rare blood cancers (MDS/MPN and CNL). The goal is to see if it can shrink enlarged spleens and improve blood counts. Participants take the drug by mouth and are monitored for response and side effects.
Matched conditions: MDS
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
New combo tackles blood cancer relapse after transplant
Disease control OngoingThis study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in people whose MDS or AML came back after a stem cell transplant. The goal is to find the best dose and see if the treatment can control the cancer. About 55 adults with relapsed dis…
Matched conditions: MDS
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
Smartphone app tracks blood transfusion impact in MDS patients
Knowledge-focused OngoingThis study follows 60 people with lower-risk myelodysplastic neoplasms (MDS) for 6 months to see how different blood transfusion strategies affect their quality of life. Participants use a smartphone app or paper questionnaires to report symptoms weekly, and doctors collect routi…
Matched conditions: MDS
Sponsor: University of Leipzig • Aim: Knowledge-focused
Last updated May 04, 2026 16:21 UTC